



MAYNE PHARMA ANNOUNCES EXPANSION OF US PRODUCTION SPACE

24 June 2020, Greenville, NC: Mayne Pharma today announced expansion of its Greenville, North Carolina production facility to support projected growth of the company's portfolio and third party contract manufacturing business.

The expansion will add 3,760 square feet of production space to the current facility and will consist of three new rooms: one dispensing/flex room, one tablet press room and one flex room to accommodate an increase in customer products. The space will house key equipment, including a Fette FE55 tablet press, a Bosch 720 encapsulator, and a weigh and dispense isolator.

"The new equipment we've purchased is ideal for small batch size and high changeover products," said Troy Woelfel, Vice President and General Manager of Greenville Operations. "Growing our manufacturing capabilities reflects our commitment to providing our customers with quality services from concept through to commercialization."

The Fette FE55 can produce more than 90 percent of all tablet types and is known for its production efficiency and high yields. It enables quick changeover of product mix, has bi-layer capacity, and features containment capabilities for the safe handling of potent products.

The Bosch 720 encapsulator has an output of 720 capsules per minute. It achieves process precision, high yields, stability in capsule filling and offers containment for the safe handling of potent products. The weigh and dispense isolator offers the same safe potent product handling ability while increasing capacity for weighing and dispensing product and includes low humidity control.

According to Woelfel, construction is expected to commence in August 2020 and be operational in early 2021. Woelfel adds, "Mayne Pharma is well-positioned to respond to both the evolving industry landscape and to the increasing demand for our services."

For further information contact:

Tom Salus +1 252 707 6068, thomas.salus@maynepharma.com



ASX Announcement

About Mayne Pharma

Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on applying its drug delivery expertise to commercialise branded and generic pharmaceuticals, offering patients better and more accessible medicines. Mayne Pharma also provides contract development and manufacturing services to more than 100 clients worldwide.

Mayne Pharma has a 40-year track record of innovation and success in developing new oral drug delivery systems and these technologies have been successfully commercialised in numerous products that continue to be marketed around the world.

Mayne Pharma has two facilities based in Salisbury, Australia and Greenville, USA with expertise in the formulation of complex oral and topical dose forms including potent compounds, modified-release products and poorly soluble compounds. For further information, visit www.maynepharma.com